ClinicalTrials.gg
CompletedNCT02775903Updated Feb 28, 2023Results posted

An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)

A Phase 2 interventional study of Azacitidine and Durvalumab in Leukemia, Myeloid, Acute and Myelodysplastic Syndromes, sponsored by Celgene. Completed at 103 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-28.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
213
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 43 studies in Leukemia, Myeloid, Acute by Bristol-Myers Squibb — 1 open to participants now, 4 under way, none of them phase 3. Leukemia, Myeloid, Acute · Bristol-Myers Squibb.

Enrollment
4th of 30
213 · median 38
Started
2016
with 4 others
Phase 2
8 of 43
none open now
Registered
23rd of 43
by date

Among the 43 studies in Leukemia, Myeloid, Acute by Bristol-Myers Squibb, this one is the 4th largest by enrollment of the 30 interventional ones that give a count, is one of 5 that started in 2016, is one of 8 in phase 2, and was the 23rd registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 813 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

1 of the 43 studies in Leukemia, Myeloid, Acute by Bristol-Myers Squibb is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 621 Leukemia, Myeloid, Acute studies recruiting now, 361 (58%) set no upper age limit and 220 (35%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Leukemia, Myeloid, Acute by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the efficacy of subcutaneous azacitidine in combination with durvalumab as compared with subcutaneous azacitidine alone in adults with previously untreated, higher risk MDS who are not eligible for HSCT or in adults ≥ 65 years old with previously untreated AML who are not eligible for HSCT, with intermediate or poor cytogenetic risk.

03

Conditions studied

  • Leukemia, Myeloid, Acute
  • Myelodysplastic Syndromes

Keywords

  • MEDI4736
  • Durvalumab
  • Myelodysplastic Syndromes
  • Acute Myeloid Leukemia
  • Hematopoietic Stem Cell Transplantation
  • Azacitidine
  • Safety
  • Efficacy
  • PD-L1
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For both cohorts:

  1. Subject must understand and voluntarily sign an form (ICF) prior to any study-related assessments/procedures being conducted.
  2. Have an (ECOG) performance status of 0, 1, or 2.
  3. Female subjects of may participate, providing they meet the following conditions:

    1. Have 2 negative pregnancy tests as verified by the Investigator prior to starting any product (IP) therapy: serum pregnancy test at screening and negative serum or urine pregnancy test (Investigator's discretion) within 72 hours prior to starting treatment with IP (Cycle 1, Day 1). They must agree to ongoing pregnancy testing during the course of the study (before beginning each subsequent cycle of treatment), and after the last dose of any IP. This applies even if the subject practices complete abstinence from heterosexual contact.
    2. Agree to practice true abstinence (which must be reviewed on a monthly basis and source documented) or agree to the use of a highly effective method of use from 28 days prior to starting durvalumab or azacitidine, and must agree to continue using such precautions while taking durvalumab or azacitidine (including dose interruptions) and up to 90 days after the last dose of durvalumab or azacitidine. Cessation of contraception after this point should be discussed with a responsible physician.
    3. Agree to abstain from breastfeeding during study participation and for at least 90 days after the last dose of IP.
    4. Refrain from egg cell donation while taking durvalumab and for at least 90 days after the last dose of durvalumab.
  4. Male subject must:

    1. Either practice true abstinence from heterosexual contact (which must be reviewed on a monthly basis) or agree to avoid fathering a child, to use highly effective methods of contraception, male condom plus spermicide during sexual contact with a pregnant female or a female of childbearing potential (even if he has undergone a successful vasectomy) from starting dose of IP (Cycle 1 Day 1), including dose interruptions through 90 days after receipt of the last dose of durvalumab or azacitidine.
    2. Refrain from semen or sperm donation while taking IP and for at least 90 days after the last dose of IP.
  5. Understand and voluntarily sign a biomarker-specific component of the informed consent form prior to any study-related procedures conducted.
  6. Willing and able to adhere to the study visit schedule and other protocol requirements.

    MDS Cohort:

  7. Age ≥ 18 years at the time of signing the informed consent form.
  8. Central confirmation of diagnosis of previously untreated primary or secondary myelodysplastic syndromes (MDS) as per World Health Organization (WHO) classification. Results of central pathology review are required prior to receiving the first dose of IP.
  9. Central confirmation of the categorization of the MDS risk classification, as per the Revised - International prognostic scoring system (IPSS-R) Intermediate risk with >10% blasts or poor or very poor cytogenetics, or IPSS-R High or Very High risk (results of central pathology review required prior to receiving the first dose of IP).

    Acute myeloid leukemia (AML) Cohort:

  10. Age ≥ 65 years at the time of signing the informed consent form (ICF).
  11. Central confirmation of diagnosis of one of the following untreated AML as per WHO classification:

    • Newly diagnosed, confirmed de novo AML (bone marrow blasts ≥ 20%), or
    • AML secondary to prior MDS, or
    • AML secondary to exposure to potentially leukemogenic therapies or agents (eg, radiation therapy, alkylating agents, topoisomerase II inhibitors) with the primary in remission for at least 2 years.
  12. Central confirmation of intermediate or poor risk status, based on Cytogenetics for acute myeloid leukemia.

Exclusion criteria

Exclusion Criteria:

For both cohorts:

  1. Prior hematopoietic stem cell transplant.
  2. Considered eligible for hematopoietic stem cell transplant (allogeneic or autologous) at the time of signing the ICF.
  3. Prior exposure to azacitidine, decitabine or prior exposure to the oral formulation of decitabine, or other oral azacitidine derivative.
  4. Inaspirable bone marrow.
  5. Use of any of the following within 28 days prior to the first dose of IP:

    • Thrombopoiesis-stimulating agents (eg, romiplostim, eltrombopag, Interleukin-11)
    • Any hematopoietic growth factors (erythropoietin-stimulating agents [ESAs], granulocyte colony-stimulating factor (G-CSF) and other red blood cell (RBC) hematopoietic growth factors (eg, Interleukin-3)
    • Any investigational agents within 28 days or 5 half-lives (whichever is longer) of initiating study treatment
  6. Prior history of (except MDS for AML subjects), unless the subject has been free of the disease for ≥ 2 years. However, subjects with the following history/concurrent conditions are allowed:

    • Basal or squamous cell carcinoma of the skin
    • Carcinoma in situ of the cervix
    • Carcinoma in situ of the breast
    • Incidental histologic finding of prostate cancer (T1a or T1b using the tumor, nodes, [tumor, node, metastases (TNM)] clinical staging system).
  7. Pregnant or breast-feeding females or females who intend to become pregnant during study participation.
  8. Subject has active or prior documented or inflammatory disorders (including inflammatory bowel disease [eg, colitis, Crohn's disease], diverticulitis with the exception of a prior episode that has resolved or diverticulosis, celiac disease, irritable bowel disease [exclude only if active within the last 6 months prior to signing the ICF], or other serious gastrointestinal chronic conditions associated with diarrhea; systemic lupus erythematosus; Wegener's syndrome [granulomatosis with polyangiitis]; myasthenia gravis; Graves' disease; rheumatoid arthritis; hypophysitis, uveitis; etc) within the past 3 years prior to the start of treatment. The following are exceptions to this criterion:

    • Subjects with vitiligo or alopecia;
    • Subjects with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement for ≥ 3 months prior to signing the ICF; or
    • Subjects with psoriasis not requiring systemic treatment
  9. Significant active cardiac disease within the previous 6 months prior to signing the ICF, including:

    • (NYHA) Class III or IV congestive heart failure;
    • Unstable angina or angina requiring surgical or medical intervention; and/or
    • Significant cardiac arrhythmia
    • Myocardial infarction
  10. Uncontrolled intercurrent illness including, but not limited to, ongoing or active systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics or other treatment), uncontrolled hypertension, cardiac arrhythmia, pneumonitis, interstitial lung disease, active peptic ulcer disease or gastritis that would limit compliance with study requirement.
  11. Known (HIV) or (HCV) infection, or evidence of active virus (HBV) infection.
  12. Known or suspected to azacitidine, mannitol, or durvalumab, its constituents, or to any other humanized monoclonal antibody.
  13. Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.
  14. Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study.
  15. Prior anti-cytotoxic T-lymphocyte-associated antigen 4 (), programmed death-1 (PD-1), or programmed death ligand-1 (PD-L1) or other immune checkpoint mAb exposure.
  16. Other investigational monoclonal antibodies (mAbs) within 6 months prior to first dose of IP.
  17. Current or prior use of medication within 14 days prior to the first dose of IP. The following are exceptions to this criterion:

    • Intranasal, inhaled, topical, or local injections (eg, intra-articular injection)
    • Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or equivalent
    • Steroids as premedication for hypersensitivity reactions (eg, computed tomography [CT] scan premedication)
  18. History of primary immunodeficiency.
  19. Receipt of live, attenuated vaccine within 30 days prior to the first dose of IP (NOTE: Subjects, if enrolled, should not receive during the study and for 30 days after the last dose of durvalumab).
  20. Unwilling or unable to complete subject reported outcome assessments without assistance or with minimal assistance from trained site personnel and/or caregiver.
  21. Subjects who have had clinical evidence of central nervous system (CNS) or pulmonary leukostasis, disseminated intravascular coagulation, or CNS leukemia.
  22. Presence of advanced malignant hepatic tumors.
  23. Any of the following laboratory abnormalities:

    • Serum (AST/SGOT) or alanine aminotransferase (ALT/SGPT) > 2.5 × (ULN)
    • Serum total > 1.5 × ULN. Higher levels are acceptable if these can be attributed to active red blood cell precursor destruction within the bone marrow (ie, ineffective erythropoiesis). Subjects are excluded if there is evidence of autoimmune hemolytic anemia manifested as a corrected reticulocyte count of > 2% with either a positive Coombs' test or over 50% of indirect bilirubin
    • Serum creatinine > 2.5 × ULN.

    MDS Cohort:

  24. Any previous cytotoxic, cytostatic, hormonal, biological or immunological treatment for MDS (ESA with or without G-CSF are allowed under certain conditions, see exclusion criterion # 5).
  25. Any investigational therapy within 28 days prior to the first dose of IP.
  26. Use of hydroxyurea within 2 weeks prior to obtaining the screening hematology sample and prior to first dose of IP.
  27. Absolute white blood cell (WBC) count ≥ 15 × 10\^9/L.

    AML Cohort:

  28. Previous cytotoxic, cytostatic, hormonal, biological or immunological treatment (ESA with or without G-CSF and iron chelating therapy and hydroxyurea are allowed under certain conditions, see exclusion criterion #5) or biologic treatment for AML.
  29. Any investigational therapy within 28 days prior to the first dose of IP.
  30. Use of hydroxyurea within 2 weeks prior to obtaining the screening hematology sample and prior to first dose of IP.
  31. Prior use of targeted therapy agents (eg, FLT3 inhibitors, other kinase inhibitors).
  32. Suspected or proven acute promyelocytic leukemia (French-American-British (FAB) M3) based on morphology, immunophenotype, molecular assay, or karyotype; AML associated with t(9;22) karyotype, biphenotypic acute leukemia or AML with previous hematologic disorder such as chronic myelogenous leukemia or myeloproliferative neoplasms.
  33. Acute myeloid leukemia associated with inv(16), t(8;21), t(16;16), t(15;17) karyotypes or molecular evidence of such translocations if not associated with a c-Kit mutation.
  34. Absolute WBC count ≥ 15 × 10\^⁹/L (NOTE: Hydroxyurea is not allowed to attain a WBC count ≤ 15 x 10⁹/L).
  35. Known history or presence of Sweet Syndrome at screening
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
213 participants (actual)

Study arms

  • Experimental
    Azacitidine + Durvalumab

    Participants received 75 mg/m² subcutaneous azacitidine for 7 days every 4 weeks (Q4W) in combination with 1500 mg intravenous durvalumab on Day 1 of every 4 week cycle for at least 6 cycles. Participants who benefited from treatment may have continued treatment until loss of that benefit, disease progression or other treatment discontinuation criterion were met.

    Drug: Azacitidine · Biological: Durvalumab

  • Active comparator
    Azacitidine Alone

    Participants received 75 mg/m² subcutaneous azacitidine for 7 days every 4 weeks for at least 6 cycles. Participants who benefited from treatment may have continued treatment until loss of that benefit, disease progression or other treatment discontinuation criterion were met.

    Drug: Azacitidine

Interventions

  • Administered by subcutaneous injection on Days 1 to 7 of each 4-week treatment cycle.

  • BiologicalDurvalumab

    Administered by intravenous infusion on Day 1 of every 4-week treatment cycle.

    Also known as: MEDI4736

06

What researchers measure

Primary outcomes

  1. MDS Cohort: Overall Response Rate

    Overall response rate (ORR) is defined as the percentage of participants achieving a complete remission (CR), partial remission (PR), marrow complete remission (mCR), and/or hematological improvement (HI) based on International Working Group (IWG) 2006 response criteria for MDS and central review. CR: ≤ 5% myeloblasts in bone marrow (BM), and peripheral blood: hemoglobin ≥ 11 g/dL; platelets ≥ 100 × 10⁹/L; neutrophils ≥ 1.0 × 10⁹/L; blasts 0% PR: BM blasts decreased by ≥ 50% but still \> 5%; peripheral blood as for CR mCR: BM ≤ 5% myeloblasts and decrease by ≥ 50% HI: Any of the following: •Hemoglobin increase by ≥ 1.5 g/dL or reduction of units of red blood cell (RBC) transfusions of at least 4 RBC transfusions/8 weeks compared with pretreatment •Absolute increase in platelets of ≥ 30 × 10⁹/L if pretreatment value \> 20 × 10⁹/L or increase from \< 20 × 10⁹/L to \> 20 × 10⁹/L and by at least 100% •At least 100% increase in neutrophils and an absolute increase of \> 0.5 × 10⁹/L

    Time frame: Response was assessed following every 3 treatment cycles until treatment discontinuation; median duration of treatment was 239 days (AZA) and 215 days (DUR) in the AZA + DUR group and 210 days in the AZA alone group.

  2. AML Cohort: Overall Response Rate

    Overall response rate for AML is defined as the percentage of participants achieving an overall response of morphologic complete remission (CR) or morphologic complete remission with incomplete blood count recovery (CRi) based on modified IWG 2003 response criteria for AML and central review. CR: The following conditions must be met: •Absolute neutrophil count (ANC) ≥ 1.0 x10⁹/L •Platelet count ≥ 100 x10⁹/L •The bone marrow should contain less than 5% blast cells; •Auer rods should not be detectable; •No platelet, or whole blood transfusions for 7days prior to the date of the hematology assessment. CRi: Defined as a morphologic complete remission but the ANC count may be \< 1.0 x10⁹/L and/or the platelet count may be \< 100 x10⁹/L.

    Time frame: Response was assessed following every 3 treatment cycles until treatment discontinuation; median duration of treatment was 198 days (AZA) and 171 days (DUR) in the AZA + DUR group and 203 days in the AZA alone group.

Secondary outcomes

  1. MDS Cohort: Kaplan Meier Estimate of Time to First Response

    Time to first response is defined as the time from randomization to the earliest date any response (complete remission (CR), partial remission (PR), marrow complete remission (mCR), and/or hematological improvement (HI)) based on International Working Group (IWG) 2006 response criteria for MDS and central review. Participants who did not achieve any defined response were censored at the date of last adequate response assessment, disease progression, or death, whichever occurred first. Response was assessed following every 3 treatment cycles until treatment discontinuation.

    Time frame: From randomization to the earliest date any response (up to approximately 34 months)

  2. MDS Cohort: Kaplan Meier Estimate of Relapse-free Survival

    Relapse-free survival is defined as the time from the date of first documented response (complete remission (CR), partial remission (PR)) to the date of disease relapse or death from any cause, whichever occurred first according to the International Working Group (IWG) 2006 response criteria for MDS and central review. Participants who were still alive and progression-free were censored at the date of their last response assessment. Participants who received a subsequent therapy before the date of disease relapse or death were censored at the time of subsequent therapy. Relapse after CR or PR is defined as at least one of the following: •Return to pretreatment bone marrow blast % •Decrement of ≥ 50% from maximum remission/response levels in granulocytes or platelets •Reduction in hemoglobin concentration by ≥ 1.5 g/dL or transfusion dependence. Response was assessed following every 3 treatment cycles until treatment discontinuation.

    Time frame: From randomization to to the date of disease relapse or death from any cause, whichever occurred first (up to approximately 34 months)

  3. MDS Cohort: Percentage of Participants Who Achieved a Cytogenetic Response

    Cytogenetic response is defined as the percentage of participants who achieved a complete cytogenetic response or partial cytogenetic response according to the International Working Group (IWG) 2006 response criteria and central review. Complete cytogenetic response: Disappearance of the baseline chromosomal abnormality without appearance of new abnormalities. Partial cytogenetic response: At least 50% reduction of the chromosomal abnormality. Response was assessed following every 3 treatment cycles until treatment discontinuation.

    Time frame: From randomization up to approximately 34 months

  4. MDS Cohort: Kaplan-Meier Estimate of Progression-free Survival (PFS)

    Progression-free survival is defined as the time from randomization to the first documented progressive disease (PD), relapse, or death due to any cause during or after the treatment period, whichever occurred first, according to the International Working Group (IWG) 2006 response criteria for MDS and central review. Participants who were still alive and progression-free were censored at the date of their last response assessment. Progressive disease is defined as follows: - an increase in BM blasts relative to nadir: •If nadir less than 5% blasts: ≥ 50% increase in blasts to \> 5% blasts •If nadir 5% - 10% blasts: ≥ 50% increase in blasts to \> 10% blasts •If nadir 10% - 20% blasts: ≥ 50% increase in blasts to \> 20% blasts •If nadir 20% - 30% blasts: ≥ 50% increase in blasts to \> 30% blasts And any of the following: •At least 50% decrement from maximum remission/response levels in granulocytes or platelets •Reduction in Hgb concentration by ≥ 2 g/dL •Transfusion dependence

    Time frame: From randomization to the first documented progressive disease (PD), relapse, or death due to any cause (up to approximately 34 months)

  5. MDS Cohort: Kaplan-Meier Estimate of Duration of Response

    Duration of response is defined as the time from when the first overall response (complete remission (CR), partial remission (PR), marrow complete remission (mCR), and/or hematological improvement (HI)) was observed until relapse, progressive disease (PD), or death, as defined by the International Working Group (IWG) 2006 response criteria and central review. If no relapse, PD, or death was observed, the duration of response was censored at the last response assessment date that the participant was known to be progression-free. Response was assessed following every 3 treatment cycles until treatment discontinuation.

    Time frame: From randomization to the first overall response, or death (up to approximately 34 months)

  6. MDS Cohort: Kaplan-Meier Estimate of Time to AML Transformation

    Participants were monitored for transformation to acute myeloid leukemia (AML) until death, lost to follow-up, withdrawal of consent for further data collection, or the end of the trial. Time to transformation to AML is defined as the time from the date of randomization until the date the participant had documented transformation to AML (defined as at least 30% of myeloblasts in the bone marrow). Participants with no transformation to AML were censored at the date of their last disease assessment.

    Time frame: From randomization to the date the participant had documented transformation to AML (up to approximately 34 months)

  7. MDS Cohort: Percentage of Participants With Disease Transformation to AML

    Disease transformation to acute myeloid leukemia (AML) is defined as at least 30% myeloblasts in the bone marrow. Participants were monitored for transformation to AML until death, lost to follow-up, withdrawal of consent for further data collection, or the end of the trial. Participants with no transformation to AML were censored at the date of their last disease assessment.

    Time frame: From randomization until death, lost to follow-up, withdrawal of consent for further data collection, or the end of the trial (up to approximately 34 months)

  8. AML Cohort: Kaplan Meier Estimate of Time to First Response

    Time to first response is defined as the time between the date of randomization and the earliest date any response (CR or CRi) was observed based on the modified International Working Group (IWG) 2003 response criteria for AML and central review. Participants who did not achieve any defined response were censored at the date of last adequate response assessment, disease progression, or death, whichever occurred first. Response was assessed following every 3 treatment cycles until treatment discontinuation.

    Time frame: From randomization and the earliest date any response (up to approximately 34 months)

  9. AML Cohort: Kaplan Meier Estimate of Relapse-free Survival

    Relapse-free survival is defined as time from the date of first documented response (morphologic complete remission (CR) or morphologic complete remission with incomplete blood count recovery (CRi)) to the date of disease relapse or death from any cause, whichever occurred first based on the modified International Working Group (IWG) 2003 response criteria for AML and central review. Participants who were still alive and progression-free were censored at the date of their last response assessment. Participants who received a subsequent therapy before the date of disease relapse or death were censored at the time of subsequent therapy.

    Time frame: From randomization to the date of disease relapse or death from any cause, whichever occurred first (up to approximately 34 months)

  10. AML Cohort: Percentage of Participants Who Achieved a Complete Cytogenetic Response

    Complete cytogenetic response (CyCR) based on the modified International Working Group (IWG) 2003 response criteria is defined as morphologic complete remission with a reversion to a normal karyotype. The following conditions must be met: • Absolute neutrophil count (ANC) ≥ 1.0 x10⁹/L • Platelet count ≥ 100 x10⁹/L • The bone marrow should contain less than 5% blast cells; • Auer rods should not be detectable; • No platelet, or whole blood transfusions for 7days prior to the date of the hematology assessment. AND • Reversion to normal karyotype at time of CR (based on ≥ 10 metaphases). Response was assessed following every 3 treatment cycles until treatment discontinuation.

    Time frame: From randomization up to approximately 34 months)

  11. AML Cohort: Percentage of Participants With Hematologic Improvement

    Hematological improvement was defined as participants with a erythroid response (HI-E), platelet response (HI-P) or neutrophil response (HI-NE) for at least 8 weeks, according to the IWG 2006 response criteria: Hi-E (in participants with pretreatment hemoglobin \< 11 g/dL or red blood cell (RBC)-transfusion dependent): Hemoglobin increase of ≥ 1.5 g/dL, or reduction in units of RBC transfusions of at least 4 RBC transfusions/8 weeks compared with the 8 weeks prior to pretreatment. HI-P (in participants with pretreatment platelet count \< 100 × 10⁹/L): Absolute increase in platelets of ≥ 30 × 10⁹/L if pretreatment value \> 20 × 10⁹/L or increase from \< 20 × 10⁹/L to \> 20 × 10⁹/L and by at least 100%. HI-N (in participants with pretreatment neutrophils \< 1.0 × 10⁹/L): At least 100% increase in neutrophils and an absolute increase of \> 0.5 × 10⁹/L. Response was assessed following every 3 treatment cycles until treatment discontinuation.

    Time frame: From randomization up to approximately 34 months

  12. AML Cohort: Kaplan-Meier Estimate of Duration of Response

    Duration of response is defined as the time from the first response morphologic complete remission (CR) or morphologic complete remission with incomplete blood count recovery (CRi)) was observed until relapse, PD, or death based on the IWG 2003 response criteria and central review. If no relapse, PD, or death was observed, the duration of response was censored at the last response assessment date that the participant was known to be progression-free. Response was assessed following every 3 treatment cycles until treatment discontinuation.

    Time frame: From randomization until relapse, PD, or death (up to approximately 34 months)

  13. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    Treatment emergent adverse events are adverse events (AEs) that occurred or worsened on or after the first dose of study drug (durvalumab or azacitidine) and within 90 days after last dose of durvalumab or 28 days after last dose of azacitidine. A treatment-related TEAE is a TEAE where the causal relationship was assessed by the investigator as "Suspected". The intensity of AEs was graded according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03: Grade 1 (Mild): asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 (Moderate): minimal, local or noninvasive intervention indicated; limiting age-appropriate activities of daily living. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death due to AE.

    Time frame: From first dose to 90 days after last dose of durvalumab or 28 days after last dose of azacitidine proir to the extension study (up to approximately 34 months)

  14. Kaplan-Meier Estimate of Overall Survival

    Overall survival is defined as the time between randomization and death/censored date. Participants who were alive at the time of the clinical data cut-off were censored at the last known alive date.

    Time frame: From randomization to date of death or last known alive date (up to approximately 34 months)

  15. One-year Survival

    One-year survival is defined as the probability of survival at 1 year from randomization and is represented by the Kaplan-Meier estimate of the percentage of participants alive after 1 year.

    Time frame: At 12 months after randomization

  16. Durvalumab Serum Concentration

    Time frame: Cycle 1 Day 1 end of infusion (EOI), Cycle 2 Day 1 pre-infusion, Cycle 4 Day 1 pre-infusion and EOI, and Cycle 6 Day 1 pre-infusion

  17. Change From Baseline in Selected Hematology Parameters I

    Baseline values are defined as the last assessment of a particular parameter prior to administration of the participants first dose.

    Time frame: Baseline and last lab measurement collected in Cycle 2 (Last measurement could be taken either on Day 1, 8, 15 or 22)

  18. Change From Baseline in Selected Hematology Parameters II

    Baseline values are defined as the last assessment of a particular parameter prior to administration of the participants first dose.

    Time frame: Baseline and last lab measurement collected in Cycle 2 (Last measurement could be taken either on Day 1, 8, 15 or 22)

  19. Change From Baseline in Selected Chemistry Parameters I

    Baseline values are defined as the last assessment of a particular parameter prior to administration of the participants first dose.

    Time frame: Baseline and last lab measurement collected in Cycle 2 (Last measurement could be taken either on Day 1, 8, 15 or 22)

  20. Change From Baseline in Selected Chemistry Parameters II

    Baseline values are defined as the last assessment of a particular parameter prior to administration of the participants first dose.

    Time frame: Baseline and last lab measurement collected in Cycle 2 (Last measurement could be taken either on Day 1, 8, 15 or 22)

  21. Change From Baseline in Selected Chemistry Parameters III

    Baseline values are defined as the last assessment of a particular parameter prior to administration of the participants first dose.

    Time frame: Baseline and last lab measurement collected in Cycle 2 (Last measurement could be taken either on Day 1, 8, 15 or 22)

  22. Change From Baseline in Selected Chemistry Parameters IV

    Baseline values are defined as the last assessment of a particular parameter prior to administration of the participants first dose.

    Time frame: Baseline and last lab measurement collected in Cycle 2 (Last measurement could be taken either on Day 1, 8, 15 or 22)

07

Results

Posted May 4, 2020
Limitations and caveats
Protocol Amendment 03 was introduced on 05 Mar 2019. At the Investigator's discretion, participants meeting all the continuation criteria were eligible to enter the optional extension phase to continue to benefit from treatment with subcutaneous azacitidine and/or durvalumab. Participants started the extension phase at the time of their next regularly scheduled dosing cycle for study drug azacitidine or azacitidine and durvalumab.

Participant flow

This study consisted of 2 cohorts: • Adults with previously untreated intermediate, high or very high risk myelodysplastic syndromes (MDS) not eligible for hematopoietic stem cell transplantation (HSCT). • Adults with previously untreated acute myeloid leukemia (AML) ≥ 65 years and not eligible for HSCT with intermediate or poor cytogenetic risk.

Participant flow — Overall Study
MilestoneMDS: Azacitidine + DurvalumabMDS: Azacitidine AloneAML: Azacitidine + DurvalumabAML: Azacitidine Alone
Started42426465
Completed4115
Not completed38416360
Withdrew: Death7111211
Withdrew: Adverse event01123
Withdrew: Progressive disease15143020
Withdrew: Lack of efficacy2226
Withdrew: Withdrawal by subject7558
Withdrew: Other reasons78212

Outcome measures

PrimaryMDS Cohort: Overall Response Rate

Overall response rate (ORR) is defined as the percentage of participants achieving a complete remission (CR), partial remission (PR), marrow complete remission (mCR), and/or hematological improvement (HI) based on International Working Group (IWG) 2006 response criteria for MDS and central review. CR: ≤ 5% myeloblasts in bone marrow (BM), and peripheral blood: hemoglobin ≥ 11 g/dL; platelets ≥ 100 × 10⁹/L; neutrophils ≥ 1.0 × 10⁹/L; blasts 0% PR: BM blasts decreased by ≥ 50% but still \> 5%; peripheral blood as for CR mCR: BM ≤ 5% myeloblasts and decrease by ≥ 50% HI: Any of the following: •Hemoglobin increase by ≥ 1.5 g/dL or reduction of units of red blood cell (RBC) transfusions of at least 4 RBC transfusions/8 weeks compared with pretreatment •Absolute increase in platelets of ≥ 30 × 10⁹/L if pretreatment value \> 20 × 10⁹/L or increase from \< 20 × 10⁹/L to \> 20 × 10⁹/L and by at least 100% •At least 100% increase in neutrophils and an absolute increase of \> 0.5 × 10⁹/L

Time frame:
Response was assessed following every 3 treatment cycles until treatment discontinuation; median duration of treatment was 239 days (AZA) and 215 days (DUR) in the AZA + DUR group and 210 days in the AZA alone group.
Reported as:
Number · percentage of participants
MDS Cohort: Overall Response Rate
percentage of participantsMDS: Azacitidine + DurvalumabMDS: Azacitidine Alone
MDS Cohort: Overall Response Rate61.9 (47.22 to 76.59)47.6 (32.51 to 62.72)
Statistical analysis
  • MDS: Azacitidine + Durvalumab vs MDS: Azacitidine Alone · Wald asymptotic two-sided test · p = 0.1838
PrimaryAML Cohort: Overall Response Rate

Overall response rate for AML is defined as the percentage of participants achieving an overall response of morphologic complete remission (CR) or morphologic complete remission with incomplete blood count recovery (CRi) based on modified IWG 2003 response criteria for AML and central review. CR: The following conditions must be met: •Absolute neutrophil count (ANC) ≥ 1.0 x10⁹/L •Platelet count ≥ 100 x10⁹/L •The bone marrow should contain less than 5% blast cells; •Auer rods should not be detectable; •No platelet, or whole blood transfusions for 7days prior to the date of the hematology assessment. CRi: Defined as a morphologic complete remission but the ANC count may be \< 1.0 x10⁹/L and/or the platelet count may be \< 100 x10⁹/L.

Time frame:
Response was assessed following every 3 treatment cycles until treatment discontinuation; median duration of treatment was 198 days (AZA) and 171 days (DUR) in the AZA + DUR group and 203 days in the AZA alone group.
Reported as:
Number · percentage of participants
AML Cohort: Overall Response Rate
percentage of participantsAML: Azacitidine + DurvalumabAML: Azacitidine Alone
AML Cohort: Overall Response Rate31.3 (19.89 to 42.61)35.4 (23.76 to 47.01)
Statistical analysis
  • AML: Azacitidine + Durvalumab vs AML: Azacitidine Alone · Wald asymptotic two-sided test · p = 0.6180
SecondaryMDS Cohort: Kaplan Meier Estimate of Time to First Response

Time to first response is defined as the time from randomization to the earliest date any response (complete remission (CR), partial remission (PR), marrow complete remission (mCR), and/or hematological improvement (HI)) based on International Working Group (IWG) 2006 response criteria for MDS and central review. Participants who did not achieve any defined response were censored at the date of last adequate response assessment, disease progression, or death, whichever occurred first. Response was assessed following every 3 treatment cycles until treatment discontinuation.

Time frame:
From randomization to the earliest date any response (up to approximately 34 months)
Reported as:
Median · Weeks
MDS Cohort: Kaplan Meier Estimate of Time to First Response
WeeksMDS: Azacitidine + DurvalumabMDS: Azacitidine Alone
MDS Cohort: Kaplan Meier Estimate of Time to First Response14.3 (11.3 to 20.9)18.4 (8.1 to 26.1)
Statistical analysis
  • MDS: Azacitidine + Durvalumab vs MDS: Azacitidine Alone · Log Rank · p = 0.7016Log-rank test stratified according to the cytogenetic risk at time of randomization (very good, good and intermediate vs poor and very poor)
SecondaryMDS Cohort: Kaplan Meier Estimate of Relapse-free Survival

Relapse-free survival is defined as the time from the date of first documented response (complete remission (CR), partial remission (PR)) to the date of disease relapse or death from any cause, whichever occurred first according to the International Working Group (IWG) 2006 response criteria for MDS and central review. Participants who were still alive and progression-free were censored at the date of their last response assessment. Participants who received a subsequent therapy before the date of disease relapse or death were censored at the time of subsequent therapy. Relapse after CR or PR is defined as at least one of the following: •Return to pretreatment bone marrow blast % •Decrement of ≥ 50% from maximum remission/response levels in granulocytes or platelets •Reduction in hemoglobin concentration by ≥ 1.5 g/dL or transfusion dependence. Response was assessed following every 3 treatment cycles until treatment discontinuation.

Time frame:
From randomization to to the date of disease relapse or death from any cause, whichever occurred first (up to approximately 34 months)
Reported as:
Median · Months
MDS Cohort: Kaplan Meier Estimate of Relapse-free Survival
MonthsMDS: Azacitidine + DurvalumabMDS: Azacitidine Alone
MDS Cohort: Kaplan Meier Estimate of Relapse-free Survival3.7 (3.0 to NA)NA (0.0 to NA)
Statistical analysis
  • MDS: Azacitidine + Durvalumab vs MDS: Azacitidine Alone · Log Rank · p = 0.6076Log-rank test stratified according to the cytogenetic risk at time of randomization (very good, good and intermediate vs poor and very poor).
SecondaryMDS Cohort: Percentage of Participants Who Achieved a Cytogenetic Response

Cytogenetic response is defined as the percentage of participants who achieved a complete cytogenetic response or partial cytogenetic response according to the International Working Group (IWG) 2006 response criteria and central review. Complete cytogenetic response: Disappearance of the baseline chromosomal abnormality without appearance of new abnormalities. Partial cytogenetic response: At least 50% reduction of the chromosomal abnormality. Response was assessed following every 3 treatment cycles until treatment discontinuation.

Time frame:
From randomization up to approximately 34 months
Reported as:
Number · percentage of participants
MDS Cohort: Percentage of Participants Who Achieved a Cytogenetic Response
percentage of participantsMDS: Azacitidine + DurvalumabMDS: Azacitidine Alone
MDS Cohort: Percentage of Participants Who Achieved a Cytogenetic Response47.6 (26.26 to 68.98)34.8 (15.32 to 54.25)
Statistical analysis
  • MDS: Azacitidine + Durvalumab vs MDS: Azacitidine Alone · Wald asymptotic two-sided test · p = 0.3840
SecondaryMDS Cohort: Kaplan-Meier Estimate of Progression-free Survival (PFS)

Progression-free survival is defined as the time from randomization to the first documented progressive disease (PD), relapse, or death due to any cause during or after the treatment period, whichever occurred first, according to the International Working Group (IWG) 2006 response criteria for MDS and central review. Participants who were still alive and progression-free were censored at the date of their last response assessment. Progressive disease is defined as follows: - an increase in BM blasts relative to nadir: •If nadir less than 5% blasts: ≥ 50% increase in blasts to \> 5% blasts •If nadir 5% - 10% blasts: ≥ 50% increase in blasts to \> 10% blasts •If nadir 10% - 20% blasts: ≥ 50% increase in blasts to \> 20% blasts •If nadir 20% - 30% blasts: ≥ 50% increase in blasts to \> 30% blasts And any of the following: •At least 50% decrement from maximum remission/response levels in granulocytes or platelets •Reduction in Hgb concentration by ≥ 2 g/dL •Transfusion dependence

Time frame:
From randomization to the first documented progressive disease (PD), relapse, or death due to any cause (up to approximately 34 months)
Reported as:
Median · Months
MDS Cohort: Kaplan-Meier Estimate of Progression-free Survival (PFS)
MonthsMDS: Azacitidine + DurvalumabMDS: Azacitidine Alone
MDS Cohort: Kaplan-Meier Estimate of Progression-free Survival (PFS)8.7 (5.6 to 10.2)8.6 (3.4 to 11.2)
Statistical analysis
  • MDS: Azacitidine + Durvalumab vs MDS: Azacitidine Alone · Log Rank · p = 0.8961Log-rank test stratified according to the cytogenetic risk at time of randomization (very good, good and intermediate vs poor and very poor).
SecondaryMDS Cohort: Kaplan-Meier Estimate of Duration of Response

Duration of response is defined as the time from when the first overall response (complete remission (CR), partial remission (PR), marrow complete remission (mCR), and/or hematological improvement (HI)) was observed until relapse, progressive disease (PD), or death, as defined by the International Working Group (IWG) 2006 response criteria and central review. If no relapse, PD, or death was observed, the duration of response was censored at the last response assessment date that the participant was known to be progression-free. Response was assessed following every 3 treatment cycles until treatment discontinuation.

Time frame:
From randomization to the first overall response, or death (up to approximately 34 months)
Reported as:
Median · Weeks
MDS Cohort: Kaplan-Meier Estimate of Duration of Response
WeeksMDS: Azacitidine + DurvalumabMDS: Azacitidine Alone
MDS Cohort: Kaplan-Meier Estimate of Duration of Response33.9 (22.1 to 47.4)39.7 (26.3 to 73.1)
Statistical analysis
  • MDS: Azacitidine + Durvalumab vs MDS: Azacitidine Alone · Log Rank · p = 0.3591Log-rank test stratified according to the cytogenetic risk at time of randomization (very good, good and intermediate vs poor and very poor).
SecondaryMDS Cohort: Kaplan-Meier Estimate of Time to AML Transformation

Participants were monitored for transformation to acute myeloid leukemia (AML) until death, lost to follow-up, withdrawal of consent for further data collection, or the end of the trial. Time to transformation to AML is defined as the time from the date of randomization until the date the participant had documented transformation to AML (defined as at least 30% of myeloblasts in the bone marrow). Participants with no transformation to AML were censored at the date of their last disease assessment.

Time frame:
From randomization to the date the participant had documented transformation to AML (up to approximately 34 months)
Reported as:
Median · Months
MDS Cohort: Kaplan-Meier Estimate of Time to AML Transformation
MonthsMDS: Azacitidine + DurvalumabMDS: Azacitidine Alone
MDS Cohort: Kaplan-Meier Estimate of Time to AML Transformation20.8 (15.0 to NA)27.7 (11.3 to NA)
Statistical analysis
  • MDS: Azacitidine + Durvalumab vs MDS: Azacitidine Alone · Log Rank · p = 0.9031Log-rank test stratified according to the cytogenetic risk at time of randomization (very good, good and intermediate vs poor and very poor).
SecondaryMDS Cohort: Percentage of Participants With Disease Transformation to AML

Disease transformation to acute myeloid leukemia (AML) is defined as at least 30% myeloblasts in the bone marrow. Participants were monitored for transformation to AML until death, lost to follow-up, withdrawal of consent for further data collection, or the end of the trial. Participants with no transformation to AML were censored at the date of their last disease assessment.

Time frame:
From randomization until death, lost to follow-up, withdrawal of consent for further data collection, or the end of the trial (up to approximately 34 months)
Reported as:
Number · Percentage of participants
MDS Cohort: Percentage of Participants With Disease Transformation to AML
Percentage of participantsMDS: Azacitidine + DurvalumabMDS: Azacitidine Alone
MDS Cohort: Percentage of Participants With Disease Transformation to AML23.819.0
SecondaryAML Cohort: Kaplan Meier Estimate of Time to First Response

Time to first response is defined as the time between the date of randomization and the earliest date any response (CR or CRi) was observed based on the modified International Working Group (IWG) 2003 response criteria for AML and central review. Participants who did not achieve any defined response were censored at the date of last adequate response assessment, disease progression, or death, whichever occurred first. Response was assessed following every 3 treatment cycles until treatment discontinuation.

Time frame:
From randomization and the earliest date any response (up to approximately 34 months)
Reported as:
Median · Weeks
AML Cohort: Kaplan Meier Estimate of Time to First Response
WeeksAML: Azacitidine + DurvalumabAML: Azacitidine Alone
AML Cohort: Kaplan Meier Estimate of Time to First ResponseNA (14.3 to NA)25.3 (13.9 to 43.0)
Statistical analysis
  • AML: Azacitidine + Durvalumab vs AML: Azacitidine Alone · Log Rank · p = 0.2409Log-rank test stratified according to the cytogenetic risk at time of randomization (very intermediate vs poor).
SecondaryAML Cohort: Kaplan Meier Estimate of Relapse-free Survival

Relapse-free survival is defined as time from the date of first documented response (morphologic complete remission (CR) or morphologic complete remission with incomplete blood count recovery (CRi)) to the date of disease relapse or death from any cause, whichever occurred first based on the modified International Working Group (IWG) 2003 response criteria for AML and central review. Participants who were still alive and progression-free were censored at the date of their last response assessment. Participants who received a subsequent therapy before the date of disease relapse or death were censored at the time of subsequent therapy.

Time frame:
From randomization to the date of disease relapse or death from any cause, whichever occurred first (up to approximately 34 months)
Reported as:
Median · Months
AML Cohort: Kaplan Meier Estimate of Relapse-free Survival
MonthsAML: Azacitidine + DurvalumabAML: Azacitidine Alone
AML Cohort: Kaplan Meier Estimate of Relapse-free Survival9.5 (5.0 to 15.0)12.2 (3.5 to 19.3)
Statistical analysis
  • AML: Azacitidine + Durvalumab vs AML: Azacitidine Alone · Log Rank · p = 0.0688Log-rank test stratified according to the cytogenetic risk at time of randomization (intermediate vs poor).
SecondaryAML Cohort: Percentage of Participants Who Achieved a Complete Cytogenetic Response

Complete cytogenetic response (CyCR) based on the modified International Working Group (IWG) 2003 response criteria is defined as morphologic complete remission with a reversion to a normal karyotype. The following conditions must be met: • Absolute neutrophil count (ANC) ≥ 1.0 x10⁹/L • Platelet count ≥ 100 x10⁹/L • The bone marrow should contain less than 5% blast cells; • Auer rods should not be detectable; • No platelet, or whole blood transfusions for 7days prior to the date of the hematology assessment. AND • Reversion to normal karyotype at time of CR (based on ≥ 10 metaphases). Response was assessed following every 3 treatment cycles until treatment discontinuation.

Time frame:
From randomization up to approximately 34 months)
Reported as:
Number · Percentage of participants
AML Cohort: Percentage of Participants Who Achieved a Complete Cytogenetic Response
Percentage of participantsAML: Azacitidine + DurvalumabAML: Azacitidine Alone
AML Cohort: Percentage of Participants Who Achieved a Complete Cytogenetic Response11.3 (2.79 to 19.85)16.0 (5.84 to 26.16)
Statistical analysis
  • AML: Azacitidine + Durvalumab vs AML: Azacitidine Alone · Wald asymptotic two-sided test · p = 0.4894
SecondaryAML Cohort: Percentage of Participants With Hematologic Improvement

Hematological improvement was defined as participants with a erythroid response (HI-E), platelet response (HI-P) or neutrophil response (HI-NE) for at least 8 weeks, according to the IWG 2006 response criteria: Hi-E (in participants with pretreatment hemoglobin \< 11 g/dL or red blood cell (RBC)-transfusion dependent): Hemoglobin increase of ≥ 1.5 g/dL, or reduction in units of RBC transfusions of at least 4 RBC transfusions/8 weeks compared with the 8 weeks prior to pretreatment. HI-P (in participants with pretreatment platelet count \< 100 × 10⁹/L): Absolute increase in platelets of ≥ 30 × 10⁹/L if pretreatment value \> 20 × 10⁹/L or increase from \< 20 × 10⁹/L to \> 20 × 10⁹/L and by at least 100%. HI-N (in participants with pretreatment neutrophils \< 1.0 × 10⁹/L): At least 100% increase in neutrophils and an absolute increase of \> 0.5 × 10⁹/L. Response was assessed following every 3 treatment cycles until treatment discontinuation.

Time frame:
From randomization up to approximately 34 months
Reported as:
Number · Percentage of participants
AML Cohort: Percentage of Participants With Hematologic Improvement
Percentage of participantsAML: Azacitidine + DurvalumabAML: Azacitidine Alone
AML Cohort: Percentage of Participants With Hematologic Improvement42.2 (30.09 to 54.29)38.5 (26.63 to 50.29)
SecondaryAML Cohort: Kaplan-Meier Estimate of Duration of Response

Duration of response is defined as the time from the first response morphologic complete remission (CR) or morphologic complete remission with incomplete blood count recovery (CRi)) was observed until relapse, PD, or death based on the IWG 2003 response criteria and central review. If no relapse, PD, or death was observed, the duration of response was censored at the last response assessment date that the participant was known to be progression-free. Response was assessed following every 3 treatment cycles until treatment discontinuation.

Time frame:
From randomization until relapse, PD, or death (up to approximately 34 months)
Reported as:
Median · Weeks
AML Cohort: Kaplan-Meier Estimate of Duration of Response
WeeksAML: Azacitidine + DurvalumabAML: Azacitidine Alone
AML Cohort: Kaplan-Meier Estimate of Duration of Response24.6 (16.4 to 48.0)52.0 (15.1 to 84.0)
Statistical analysis
  • AML: Azacitidine + Durvalumab vs AML: Azacitidine Alone · Log Rank · p = 0.0381Log-rank test stratified according to the cytogenetic risk at time of randomization (intermediate vs poor).
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

Treatment emergent adverse events are adverse events (AEs) that occurred or worsened on or after the first dose of study drug (durvalumab or azacitidine) and within 90 days after last dose of durvalumab or 28 days after last dose of azacitidine. A treatment-related TEAE is a TEAE where the causal relationship was assessed by the investigator as "Suspected". The intensity of AEs was graded according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03: Grade 1 (Mild): asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 (Moderate): minimal, local or noninvasive intervention indicated; limiting age-appropriate activities of daily living. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death due to AE.

Time frame:
From first dose to 90 days after last dose of durvalumab or 28 days after last dose of azacitidine proir to the extension study (up to approximately 34 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsMDS: Azacitidine + DurvalumabMDS: Azacitidine AloneAML: Azacitidine + DurvalumabAML: Azacitidine Alone
Any treatment-emergent adverse event (TEAE)38416462
TEAE related to DUR27—50—
TEAE related to AZA31335650
TEAE related to DUR or AZA35335850
Grade 3 TEAE36306050
Grade 3 TEAE related to DUR18—29—
Grade 3 TEAE related to AZA18163227
Grade 3 TEAE related to DUR or AZA22163827
Grade 4 TEAE33274334
Grade 4 TEAE related to DUR16—18—
Grade 4 TEAE related to AZA19152717
Grade 4 TEAE related to DUR or AZA22152817
Grade 5 TEAE1092611
Grade 5 TEAE related to DUR2—1—
Grade 5 TEAE related to AZA1111
Grade 5 TEAE related to DUR or AZA2111
Serious TEAE34295645
Serious TEAE related to DUR11—33—
Serious TEAE related to AZA9102516
Serious TEAE related to DUR or AZA14103416
TEAE leading to discontinuation of DUR5—21—
TEAE leading to discontinuation of AZA01133
TEAE leading to discontinuation of DUR or AZA51223
TEAE leading to dose reduction of AZA36102
TEAE leading to dose interruption of DUR24—34—
TEAE leading to dose interruption of AZA27193932
TEAE leading to dose interruption of DUR or AZA28194132
TEAE leading to ongoing DUR infusion interruption2—2—
SecondaryKaplan-Meier Estimate of Overall Survival

Overall survival is defined as the time between randomization and death/censored date. Participants who were alive at the time of the clinical data cut-off were censored at the last known alive date.

Time frame:
From randomization to date of death or last known alive date (up to approximately 34 months)
Reported as:
Median · Months
Kaplan-Meier Estimate of Overall Survival
MonthsMDS: Azacitidine + DurvalumabMDS: Azacitidine AloneAML: Azacitidine + DurvalumabAML: Azacitidine Alone
Kaplan-Meier Estimate of Overall Survival11.6 (9.5 to NA)16.3 (9.8 to 22.6)13.0 (10.3 to 17.3)14.4 (10.0 to 16.6)
Statistical analysis
  • MDS: Azacitidine + Durvalumab vs MDS: Azacitidine Alone · Log Rank · p = 0.8973Log-rank test stratified according to the cytogenetic risk at time of randomization (very good, good and intermediate vs poor and very poor).
  • AML: Azacitidine + Durvalumab vs AML: Azacitidine Alone · Log Rank · p = 0.0691Log-rank test stratified according to the cytogenetic risk at time of randomization (intermediate vs poor).
SecondaryOne-year Survival

One-year survival is defined as the probability of survival at 1 year from randomization and is represented by the Kaplan-Meier estimate of the percentage of participants alive after 1 year.

Time frame:
At 12 months after randomization
Reported as:
Number · Percentage of participants
One-year Survival
Percentage of participantsMDS: Azacitidine + DurvalumabMDS: Azacitidine AloneAML: Azacitidine + DurvalumabAML: Azacitidine Alone
One-year Survival49585255
SecondaryDurvalumab Serum Concentration
Time frame:
Cycle 1 Day 1 end of infusion (EOI), Cycle 2 Day 1 pre-infusion, Cycle 4 Day 1 pre-infusion and EOI, and Cycle 6 Day 1 pre-infusion
Reported as:
Mean · ng/mL
Durvalumab Serum Concentration
ng/mLMDS: Azacitidine + DurvalumabAML: Azacitidine + Durvalumab
Cycle 1 Day 1 end of infusion375548.511 ± 140777.0558378598.369 ± 201902.4363
Cycle 2 Day 1 pre-infusion84380.032 ± 92174.345554216.956 ± 28336.3692
Cycle 4 Day 1 pre-infusion132266.794 ± 126971.622378622.429 ± 41708.9956
Cycle 4 Day 1 end of infusion433942.600 ± 233241.0329391523.395 ± 147928.1261
Cycle 6 Day 1 pre-infusion114448.977 ± 64608.9007142517.871 ± 248212.8037
SecondaryChange From Baseline in Selected Hematology Parameters I

Baseline values are defined as the last assessment of a particular parameter prior to administration of the participants first dose.

Time frame:
Baseline and last lab measurement collected in Cycle 2 (Last measurement could be taken either on Day 1, 8, 15 or 22)
Reported as:
Mean · 10^9 cells/L
Change From Baseline in Selected Hematology Parameters I
10^9 cells/LMDS: Azacitidine + DurvalumabMDS: Azacitidine AloneAML: Azacitidine + DurvalumabAML: Azacitidine Alone
Leukocytes (10^9/L)-1.330 ± 2.8158-0.497 ± 1.1452-2.050 ± 9.0236-0.941 ± 2.7708
Lymphocytes (10^9/L)-0.242 ± 0.5314-0.085 ± 0.3904-0.394 ± 1.6995-0.262 ± 0.9024
Neutrophils, Segmented (10^9/L)-0.665 ± 1.6364-0.266 ± 0.75760.646 ± 0.7870-0.102 ± 0.7346
Platelets (10^9/L)26.7 ± 112.92-2.6 ± 82.0525.9 ± 92.86-0.9 ± 167.88
SecondaryChange From Baseline in Selected Hematology Parameters II

Baseline values are defined as the last assessment of a particular parameter prior to administration of the participants first dose.

Time frame:
Baseline and last lab measurement collected in Cycle 2 (Last measurement could be taken either on Day 1, 8, 15 or 22)
Reported as:
Mean · g/L
Change From Baseline in Selected Hematology Parameters II
g/LMDS: Azacitidine + DurvalumabMDS: Azacitidine AloneAML: Azacitidine + DurvalumabAML: Azacitidine Alone
Change From Baseline in Selected Hematology Parameters II2.1 ± 15.665.7 ± 18.942.2 ± 13.67-3.0 ± 13.91
SecondaryChange From Baseline in Selected Chemistry Parameters I

Baseline values are defined as the last assessment of a particular parameter prior to administration of the participants first dose.

Time frame:
Baseline and last lab measurement collected in Cycle 2 (Last measurement could be taken either on Day 1, 8, 15 or 22)
Reported as:
Mean · g/L
Change From Baseline in Selected Chemistry Parameters I
g/LMDS: Azacitidine + DurvalumabMDS: Azacitidine AloneAML: Azacitidine + DurvalumabAML: Azacitidine Alone
Change From Baseline in Selected Chemistry Parameters I-1.8 ± 4.01-1.1 ± 2.93-1.8 ± 5.00-3.8 ± 4.78
SecondaryChange From Baseline in Selected Chemistry Parameters II

Baseline values are defined as the last assessment of a particular parameter prior to administration of the participants first dose.

Time frame:
Baseline and last lab measurement collected in Cycle 2 (Last measurement could be taken either on Day 1, 8, 15 or 22)
Reported as:
Mean · U/L
Change From Baseline in Selected Chemistry Parameters II
U/LMDS: Azacitidine + DurvalumabMDS: Azacitidine AloneAML: Azacitidine + DurvalumabAML: Azacitidine Alone
Alkaline Phosphatase (U/L)8.7 ± 15.714.5 ± 13.9012.3 ± 55.7015.5 ± 68.53
Alanine Aminotransferase (U/L)3.6 ± 16.960.4 ± 9.400.3 ± 21.054.0 ± 19.41
Aspartate Aminotransferase (U/L)0.9 ± 10.52-0.8 ± 5.73-0.9 ± 16.830.5 ± 14.22
Lipase (U/L)-5.4 ± 18.23-10.2 ± 25.80-2.0 ± 10.283.1 ± 42.85
SecondaryChange From Baseline in Selected Chemistry Parameters III

Baseline values are defined as the last assessment of a particular parameter prior to administration of the participants first dose.

Time frame:
Baseline and last lab measurement collected in Cycle 2 (Last measurement could be taken either on Day 1, 8, 15 or 22)
Reported as:
Mean · mmol/L
Change From Baseline in Selected Chemistry Parameters III
mmol/LMDS: Azacitidine + DurvalumabMDS: Azacitidine AloneAML: Azacitidine + DurvalumabAML: Azacitidine Alone
Calcium (mmol/L)0.004 ± 0.10130.016 ± 0.1008-0.003 ± 0.1523-0.039 ± 0.1189
Glucose (mmol/L)-0.40 ± 2.210-0.19 ± 1.265-0.38 ± 2.513-0.02 ± 2.365
Potassium (mmol/L)0.15 ± 0.416-0.01 ± 0.4510.02 ± 0.4110.04 ± 0.622
Sodium (mmol/L)-0.2 ± 2.930.3 ± 3.26-0.6 ± 4.49-1.6 ± 3.73
SecondaryChange From Baseline in Selected Chemistry Parameters IV

Baseline values are defined as the last assessment of a particular parameter prior to administration of the participants first dose.

Time frame:
Baseline and last lab measurement collected in Cycle 2 (Last measurement could be taken either on Day 1, 8, 15 or 22)
Reported as:
Mean · umol/L
Change From Baseline in Selected Chemistry Parameters IV
umol/LMDS: Azacitidine + DurvalumabMDS: Azacitidine AloneAML: Azacitidine + DurvalumabAML: Azacitidine Alone
Bilirubin (umol/L)2.2 ± 5.131.2 ± 4.212.4 ± 6.23-0.0 ± 5.31
Creatinine (umol/L)-4.0 ± 14.77-2.9 ± 10.192.3 ± 16.39-0.6 ± 15.93
Urate (umol/L)6.8 ± 65.85-3.2 ± 67.06-15.1 ± 75.69-29.1 ± 80.85

Adverse events

Collected over All-cause mortality was assessed from the participants first dose to their study completion (up to approximately 66 months) SAEs and Other AEs were assessed from first dose to 90 days after last dose of durvalumab or 28 days after last dose of azacitidine (up to approximately 66 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MDS: Azacitidine + Durvalumab22/38 (57.9%)34/38 (89.5%)38/38 (100%)
MDS: Azacitidine Alone27/41 (65.9%)29/41 (70.7%)40/41 (97.6%)
AML: Azacitidine + Durvalumab48/64 (75%)56/64 (87.5%)63/64 (98.4%)
AML: Azacitidine Alone42/62 (67.7%)45/62 (72.6%)60/62 (96.8%)
Most frequent serious events
Showing 10 of 191
Most frequent serious events
EventMDS: Azacitidine + DurvalumabMDS: Azacitidine AloneAML: Azacitidine + DurvalumabAML: Azacitidine Alone
Febrile neutropeniaBlood and lymphatic system disorders14/389/4123/6414/62
PneumoniaInfections and infestations6/383/4116/648/62
General physical health deteriorationGeneral disorders2/380/419/644/62
PyrexiaGeneral disorders5/383/418/645/62
NeutropeniaBlood and lymphatic system disorders4/382/413/641/62
Transformation to acute myeloid leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/384/410/640/62
AnaemiaBlood and lymphatic system disorders3/381/413/641/62
DiarrhoeaGastrointestinal disorders3/381/413/641/62
Urinary tract infectionInfections and infestations3/380/411/642/62
PneumonitisRespiratory, thoracic and mediastinal disorders1/380/415/641/62
Most frequent other events
Showing 10 of 119
Most frequent other events
EventMDS: Azacitidine + DurvalumabMDS: Azacitidine AloneAML: Azacitidine + DurvalumabAML: Azacitidine Alone
NeutropeniaBlood and lymphatic system disorders23/3821/4120/6421/62
ConstipationGastrointestinal disorders22/3820/4136/6433/62
ThrombocytopeniaBlood and lymphatic system disorders19/3818/4124/6427/62
DiarrhoeaGastrointestinal disorders16/3814/4127/6416/62
NauseaGastrointestinal disorders16/3811/4126/6422/62
AnaemiaBlood and lymphatic system disorders14/3815/4119/6419/62
Oedema peripheralGeneral disorders14/387/4118/649/62
PyrexiaGeneral disorders12/3813/4123/6421/62
CoughRespiratory, thoracic and mediastinal disorders13/3811/4118/6416/62
AstheniaGeneral disorders9/3814/4119/6412/62

Baseline characteristics

All randomized participants (intent-to-treat population)

Age, Continuous
Age, Continuous(years)MDS: Azacitidine + DurvalumabMDS: Azacitidine AloneAML: Azacitidine + DurvalumabAML: Azacitidine AloneTotal
MDS72.5 ± 6.5373.2 ± 8.83——72.8 ± 7.72
AML——76.2 ± 5.9775.3 ± 5.3675.8 ± 5.67
Age, Customized
Age, Customized(Participants)MDS: Azacitidine + DurvalumabMDS: Azacitidine AloneAML: Azacitidine + DurvalumabAML: Azacitidine AloneTotal
MDS Cohort — < 65 years210——12
MDS Cohort — ≥ 65 to < 75 years2111——32
MDS Cohort — ≥ 75 years1921——40
AML Cohort — < 65 years——000
AML Cohort — ≥ 65 to < 75 years——242852
AML Cohort — ≥ 75 years——403777
Sex: Female, Male
Sex: Female, Male(Participants)MDS: Azacitidine + DurvalumabMDS: Azacitidine AloneAML: Azacitidine + DurvalumabAML: Azacitidine AloneTotal
MDS Cohort — Female1412——26
MDS Cohort — Male2830——58
AML Cohort — Female——243458
AML Cohort — Male——403171
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)MDS: Azacitidine + DurvalumabMDS: Azacitidine AloneAML: Azacitidine + DurvalumabAML: Azacitidine AloneTotal
MDS Cohort — Hispanic or Latino52——7
MDS Cohort — Not Hispanic or Latino3033——63
MDS Cohort — Unknown or Not Reported77——14
AML Cohort — Hispanic or Latino——639
AML Cohort — Not Hispanic or Latino——394180
AML Cohort — Unknown or Not Reported——192140
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)MDS: Azacitidine + DurvalumabMDS: Azacitidine AloneAML: Azacitidine + DurvalumabAML: Azacitidine AloneTotal
MDS Cohort — American Indian or Alaska Native00——0
MDS Cohort — Asian21——3
MDS Cohort — Black or African American10——1
MDS Cohort — Native Hawaiian or Other Pacific Islander00——0
MDS Cohort — White3033——63
MDS Cohort — Not Collected or Reported75——12
MDS Cohort — Other23——5
AML Cohort — American Indian or Alaska Native——000
AML Cohort — Asian——000
AML Cohort — Black or African American——011
AML Cohort — Native Hawaiian or Other Pacific Islander——000
AML Cohort — White——454287
AML Cohort — Not Collected or Reported——182139
AML Cohort — Other——112
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)MDS: Azacitidine + DurvalumabMDS: Azacitidine AloneAML: Azacitidine + DurvalumabAML: Azacitidine AloneTotal
MDS Cohort — 0 - Fully active1718——35
MDS Cohort — 1 - Restricted but ambulatory2020——40
MDS Cohort — 2 - Ambulatory but unable to work34——7
MDS Cohort — 3 - Limited self-care00——0
MDS Cohort — 4 - Completely Disabled00——0
MDS Cohort — Missing20——2
AML Cohort — 0 - Fully active——192645
AML Cohort — 1 - Restricted but ambulatory——403272
AML Cohort — 2 - Ambulatory but unable to work——5712
AML Cohort — 3 - Limited self-care——000
AML Cohort — 4 - Completely Disabled——000
AML Cohort — Missing——000
Revised International Prognostic Scoring System (IPSS-R) Cytogenetic Risk Groups (MDS Cohort)
Revised International Prognostic Scoring System (IPSS-R) Cytogenetic Risk Groups (MDS Cohort)(Participants)MDS: Azacitidine + DurvalumabMDS: Azacitidine AloneAML: Azacitidine + DurvalumabAML: Azacitidine AloneTotal
Very good11——2
Good1010——20
Intermediate98——17
Poor89——17
Very Poor1414——28
Cytogenetic Risk Classifications (AML Cohort)
Cytogenetic Risk Classifications (AML Cohort)(Participants)MDS: Azacitidine + DurvalumabMDS: Azacitidine AloneAML: Azacitidine + DurvalumabAML: Azacitidine AloneTotal
Better risk——000
Intermediate risk——252651
Poor risk——161632
Missing——232346
08

Study locations

103 sites
  • Yale Cancer Center
    New Haven, Connecticut 06520, United States
  • Georgetown University Hospital
    Washington, District of Columbia 20007, United States
  • University of Florida
    Gainesville, Florida 32610, United States
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Duke University Medical Center
    Durham, North Carolina 27705, United States
  • Avera Cancer Institute
    Sioux Falls, South Dakota 57105, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37203, United States
  • University of Texas- MD Anderson
    Houston, Texas 77230, United States
  • Medizinische Universitat Graz
    Graz, 8036, Austria
  • Medizinische Universitat Innsbruck
    Innsbruck, 6020, Austria
  • Elisabethinen Hospital Linz
    Linz, 4020, Austria
  • Salzburger Landkliniken St. Johanns-Spital
    Salzburg, 5020, Austria
  • AKH Wien
    Wein, 1090, Austria
  • Hanusch Krankenhaus der Stadt Wien
    Wien, 1140, Austria
  • Local Institution - 653
    Wien, 1140, Austria
  • Cliniques Universitaires St-Luc
    Brussels, 1200, Belgium
  • Grand Hopital de Charleroi
    Charleroi, 6000, Belgium
  • Local Institution - 202
    Gent, 9000, Belgium
  • UH Gent
    Gent, 9000, Belgium
  • UH Gasthuisberg
    Leuven, 3000, Belgium
  • Cliniques Universitaires UCL de Mont-Godine
    Yvoir, 5530, Belgium
  • University of Alberta
    Edmonton, Alberta T6g2b7, Canada
  • CancerCare Manitoba
    Winnipeg, Manitoba R3E 0V9, Canada
  • Saint John Regional Hospital
    Saint John, New Brunswick E2L 4L2, Canada
  • Ottawa General Hospital
    Ottawa, Ontario K1H 8L6, Canada
  • Princess Margaret Cancer Centre
    Toronto, Ontario M5G 2M9, Canada
  • CHUM - Notre Dame
    Montreal, Quebec H2L 4M1, Canada
  • Centre Hospitalier Universitaire d' Angers
    Angers, 67091, France
  • Hopital Avicenne
    Bobigny Cedex, 93009, France
  • Hopital Henri Mondor
    Creteil, 94010, France
  • Centre Hospitalier Universitaire de Grenoble Hopital Albert Michallon
    La Tronche, 38700, France
  • Centre Leon Berard
    Lyon, 69008, France
  • Local Institution - 261
    Lyon, 69008, France
  • CHRU de Nantes - Hotel Dieu
    Nantes, 44093, France
  • Hopital Saint Louis
    Paris, 75010, France
  • Local Institution - 251
    Paris, 75010, France
  • CHU Bordeaux
    Pessac, 33604, France
  • Local Institution - 254
    Pessac, 33604, France
  • Centre Hospitalier Lyon Sud
    Pierre-Bénite Cedex, 69495, France
  • IUCT Oncopole
    Toulouse, 31059 Cedex 9, France
  • Local Institution - 604
    Dresden, 01307, Germany
  • Universitatsklinikum Carl Gustav Carus
    Dresden, 01307, Germany
  • Local Institution - 603
    Dusseldorf, 40479, Germany
  • Marien Hospital
    Dusseldorf, 40479, Germany
  • Universitatsklinikum Essen
    Essen, 45122, Germany
  • Klinikum der Johann Wolfgang Goethe Universitat
    Frankfurt am Main, 60590, Germany
  • Universitatsklinikum Freiburg
    Freiburg, 79106, Germany
  • Medizinische Hochschule HannoverZentrum Innere Medizin
    Hannover, 30625, Germany
  • Universitatsklinikum Leipzig
    Leipzig, 04103, Germany
  • Klinikum der LMU Campus Grosshadern
    Munchen, 1307, Germany
  • Local Institution - 605
    Munchen, 1307, Germany
  • Klinikum rechts der Isar der TU Munchen
    Munchen, 81675, Germany
  • Universitatsklinikum Ulm
    Ulm, 89081, Germany
  • AO Spedali Civili di Brescia
    Brecia, 25123, Italy
  • Azienda Ospedaliero-Universitaria Careggi
    Firenze, 50134, Italy
  • Ospedale Niguarda Milano
    Milano, 20162, Italy
  • Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello
    Palermo, 33100, Italy
  • I.R.C.C.S. Policlinico San Matteo - Universita di Pavia
    Pavia, 27100, Italy
  • Local Institution - 302
    Pavia, 27100, Italy
  • Azienda Ospedaliera Bianchi-Melacrino-Morelli
    Roma, 133, Italy
  • Local Institution - 303
    Roma, 133, Italy
  • Policlinico Agostino Gemelli - Istituto di Ematologia
    Roma, 89100, Italy
  • Azienda Ospedaliera Universitaria Policlinico Tor Vergata
    Rome, 133, Italy
  • Local Institution - 304
    Rome, 133, Italy
  • Azienda Ospedaliero-Universitaria Santa Maria della Misericordia die Udine
    Udine, 30174, Italy
  • Universita degli Studi dell'Insubria - Ospedale di Circolo e Fondazione Macchi - Varese
    Varese, 21100, Italy
  • VU University Medical Center
    Amsterdam, 1081 HV, Netherlands
  • Oddzial Hematologii Onkologicznej Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologicz
    Brzozow, 36-200, Poland
  • Katedra i Klinika Hematologii i Transplantologii Uniwersyteckie Centrum Kliniczne
    Gdansk, 80-211, Poland
  • Samodzielny Publiczny Szpital Kliniczny nr 1 Klinika Hematoonkologii i Transplantacji Szpiku
    Lubin, 20-081, Poland
  • Oddzial Hematologii Samodzielny Publiczny Zaklad Opieki Zdrowotnej MSW
    Olsztyn, 10-228, Poland
  • Klinika Hematologii Nowotworow Krwi i Transplantacji Szpiku
    Wroclaw, 50-367, Poland
  • Hospitais da Universidade de Coimbra
    Coimbra, 3000-076, Portugal
  • Instituto Portugues de Oncologia de Lisboa Francisco Gentil EPE
    Lisbon, 1099-023, Portugal
  • Ipo Instituto Portugues De Oncologia Porto
    Porto, 4200-072, Portugal
  • Local Institution - 502
    Porto, 4200-072, Portugal
  • Hospital de Sao Joao
    Porto, 4200, Portugal
  • Hospital Universitario Vall D hebron
    Barcelona, 28040, Spain
  • Hospital Clinic I Provincial de Barcelona
    Barcelona, 8036, Spain
  • Complejo Hospitalario San Pedro de Alcantara
    Caceres, 10003, Spain
  • Hospital Universitario La Princesa
    Madrid, 28006, Spain
  • Hospital Gregorio Maranon
    Madrid, 37007, Spain
  • Local Institution - 555
    Madrid, 37007, Spain
  • Hospital Universitario Virgen de la Victoria
    Malaga, 29010, Spain
  • Hospital Son Llatzer
    Palma de Mallorca, 7198, Spain
  • Hospital Universitario de Salamanca
    Salamanca, 37007, Spain
  • Hospital Virgen del Rocio
    Sevilla, 41013, Spain
  • Hospital Universitario La Fe
    Valencia, 46009, Spain
  • Local Institution - 559
    Valencia, 46009, Spain
  • Hospital Clinico Universitario de Valencia
    Valencia, 46010, Spain
  • University Hospital Birmingham
    Birmingham, B15 2TH, United Kingdom
  • St James University Hospital
    Leeds, LS1 3EX, United Kingdom
  • University College London Hospital
    London Bloomsbury, WC1E 6AU, United Kingdom
  • St Bartholomews Hospital
    London, EC1 7BE, United Kingdom
  • Kings College Hospital
    London, SE5 9RS, United Kingdom
  • The Christie NHS Foundation Trust
    Manchester, M20 4BX, United Kingdom

Showing the first 100 of 103 sites across 12 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Zeidan AM, Boss I, Beach CL, Copeland WB, Thompson E, Fox BA, Hasle VE, Ogasawara K, Cavenagh J, Silverman LR, Voso MT, Hellmann A, Tormo M, O'Connor T, Previtali A, Rose S, Garcia-Manero G. A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes. Blood Adv. 2022 Apr 12;6(7):2207-2218. doi: 10.1182/bloodadvances.2021005487. PubMed 34972214 ↗
  • Zeidan AM, Boss I, Beach CL, Copeland WB, Thompson E, Fox BA, Hasle VE, Hellmann A, Taussig DC, Tormo M, Voso MT, Cavenagh J, O'Connor T, Previtali A, Rose S, Silverman LR. A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML. Blood Adv. 2022 Apr 12;6(7):2219-2229. doi: 10.1182/bloodadvances.2021006138. PubMed 34933333 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2016 to primary completion in Dec 2018, 30 months.

Results were first posted in May 2020, 1 year 4 months after primary completion.

Of 57 industry-sponsored phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 55. This study's 30 months is below that.

Counting every sponsor, half of 442 studies reached it within 60 months; a quarter within 38 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2016
First posted
May 18, 2016
StartActual
Jun 3, 2016
Primary completionActual
Dec 31, 2018
CompletionActual
Dec 27, 2021
Results first posted
May 4, 2020
Last update
Feb 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02775903
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
May 18, 2016
Start date
Jun 3, 2016
Primary completion
Dec 31, 2018
Completion
Dec 27, 2021
Results posted
May 4, 2020
Last update
Feb 28, 2023

Study contacts

CL Beach, Pharm D
study director · Celgene Corporation

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Durvalumab

Start the discussion